Sanofi's valuations are attractive: Why it is stock pick of week Synopsis Despite being a mid-cap pharma company, analysts continue to impose their faith in Sanofi India due to its long term growth outlook. Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its